The Medical Letter on Drugs and Therapeutics
Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Metastatic Melanoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved two new oral kinase inhibitors for treatment of unresectable or metastatic melanoma: dabrafenib (Tafinlar – GSK) for melanomas with BRAF V600E mutations and trametinib (Mekinist – GSK) for melanomas with either BRAF V600E or V600K mutations. Dabrafenib is not recommended for patients with wild-type BRAF (BRAF-negative) melanoma, and trametinib is not recommended for patients who have received prior BRAF-inhibitor therapy.

STANDARD TREATMENT — BRAF V600E mutations are found in about 30-60% and BRAF V600K mutations are in about 10% of metastatic melanomas. First-line therapy for BRAF V600E mutant unresectable or metastatic melanoma is vemurafenib (Zelboraf), the first BRAF inhibitor approved by the FDA.1 For BRAF wild-type unresectable or metastatic melanoma, first-line therapy includes ipilimumab (Yervoy), an injectable ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Metastatic Melanoma
Article code: 1422b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian